Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 6/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6587471 | 0.76 | POLB (0.48) | PDE4DTSHRPDE4APDE4BPDE4C | |
| SCHEMBL6587183 | 0.75 | APP (0.49) | PDE4DKMT2AMEN1 | |
| SCHEMBL21823724 | 0.74 | ERN1 (0.51) | PDE4DLMNAKMT2APDE4APDE4B | |
| SCHEMBL8291670 | 0.73 | PDE4D (0.39) | PDE4DLMNAKMT2APDE4BALDH1A1 | |
| SCHEMBL6586929 | 0.72 | PDE4B (0.60) | PDE4DPDE4APDE4BPDE4C | |
| SCHEMBL26127365 | 0.72 | LMNA (0.50) | TSHRLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL7424191 | 0.72 | KMT2A (0.41) | PDE4DLMNAKMT2APDE4APDE4B | |
| SCHEMBL6585029 | 0.71 | PDE4B (0.43) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| SCHEMBL3680848 | 0.71 | PDE4D (0.54) | PDE4DLMNAKMT2APDE4APDE4B | |
| SCHEMBL6582645 | 0.71 | HMGCR (0.46) | PDE4DPDE4APDE4BPDE4CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | ZAMBON GROUP S.P.A | 2004-03-04 | — | — | US | disclosed |
| EP-1042300-B1 | PHTHALAZINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-02-11 | — | — | EP | disclosed |
| US-6589951-B1 | N right-arrowO derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF pharmaceutically acceptable salt thereof are PDE 4 and TNF alpha inhibitors. | ZAMBON GROUP S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
| US-6498160-B2 | FOR THERAPY OF EMPHYSEMA, CHRONIC BRONCHITIS, ASTHMA AND ALLERGIC RHINITIS | ZAMBON GROUP S.P.A. (IT) | 2002-12-24 | — | — | US | disclosed |
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | ZAMBON GROUP S.P.A. (IT) | 2002-05-16 | — | — | US | disclosed |
| US-6340684-B1 | TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, ALLERGIC RHINITIS | ZAMBON GROUP S.P.A. (IT) | 2002-01-22 | — | — | US | disclosed |
| EP-1098886-A1 | PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2001-05-16 | — | — | EP | disclosed |
| EP-1042300-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000005219-A1 | PHTHALAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999032456-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | PDE4D 7/4885TSHR 3420/4885LMNA 3482/4885 |
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | PDE5A, PDE3B, PDE3A | PDE4D 22/4885TSHR 2057/4885LMNA 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.